MEROPENEM by Novartis is [see microbiology ()] . Approved for complicated skin, skin structure infections (csssi) due to staphylococcus aureus (methicillin-susceptible isolates only), streptococcus pyogenes and 14 more indications. First approved in 2011.
Drug data last refreshed 19h ago
[see Microbiology ()] .
Worked on MEROPENEM at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP
Assess the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Meropenem-Pralubactam (Meropenem/FL058) in China Healthy Adult Participants
Cefepime-taniborbactam vs Meropenem in Adults With VABP or Ventilated HABP
Evaluation of the Concentration of ANT3310 and Meropenem in the Lung in Healthy Adult Participants
Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections